INNT vs. NOVN, NOVNQ, GNCA, HTGMQ, KLDO, VIVE, AHPI, HGEN, ONCSQ, and CNTX
Should you be buying Innovate Biopharmaceuticals stock or one of its competitors? The main competitors of Innovate Biopharmaceuticals include Novan (NOVN), NVN Liquidation (NOVNQ), Genocea Biosciences (GNCA), HTG Molecular Diagnostics (HTGMQ), Kaleido Biosciences (KLDO), Viveve Medical (VIVE), Allied Healthcare Products (AHPI), Humanigen (HGEN), OncoSec Medical (ONCSQ), and Context Therapeutics (CNTX). These companies are all part of the "medical" sector.
Innovate Biopharmaceuticals (NASDAQ:INNT) and Novan (NASDAQ:NOVN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
Innovate Biopharmaceuticals has a beta of -0.39, suggesting that its stock price is 139% less volatile than the S&P 500. Comparatively, Novan has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500.
Innovate Biopharmaceuticals has a net margin of 0.00% compared to Novan's net margin of -128.61%. Innovate Biopharmaceuticals' return on equity of 0.00% beat Novan's return on equity.
Innovate Biopharmaceuticals has higher earnings, but lower revenue than Novan.
5.9% of Innovate Biopharmaceuticals shares are owned by institutional investors. Comparatively, 14.5% of Novan shares are owned by institutional investors. 7.9% of Innovate Biopharmaceuticals shares are owned by company insiders. Comparatively, 1.3% of Novan shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Novan received 36 more outperform votes than Innovate Biopharmaceuticals when rated by MarketBeat users. However, 65.48% of users gave Innovate Biopharmaceuticals an outperform vote while only 56.37% of users gave Novan an outperform vote.
In the previous week, Innovate Biopharmaceuticals had 2 more articles in the media than Novan. MarketBeat recorded 3 mentions for Innovate Biopharmaceuticals and 1 mentions for Novan. Innovate Biopharmaceuticals' average media sentiment score of 0.00 equaled Novan'saverage media sentiment score.
Summary
Innovate Biopharmaceuticals and Novan tied by winning 6 of the 12 factors compared between the two stocks.
Get Innovate Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innovate Biopharmaceuticals Competitors List
Related Companies and Tools
